Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06150820
Registration number
NCT06150820
Ethics application status
Date submitted
21/11/2023
Date registered
29/11/2023
Titles & IDs
Public title
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
Query!
Scientific title
A Study to Evaluate Seroprevalence of Antibodies to AAV8 and Assessment of Biomarkers in Patients With Late-Onset Pompe Disease
Query!
Secondary ID [1]
0
0
AT845-02
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pompe Disease (Late-onset)
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - No Intervention
Other: Participants with Late-Onset Pompe Disease - Adolescent or adult participants with LOPD.
Other interventions: No Intervention
No investigational drug will be administered to participants in this study.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Occurrence of total antibodies to AAV8
Query!
Assessment method [1]
0
0
Antibodies to AAV8 will be recorded from serum blood samples collected.
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Primary outcome [2]
0
0
Occurrence of neutralizing antibodies to AAV8
Query!
Assessment method [2]
0
0
Antibodies to AAV8 will be recorded from serum blood samples collected.
Query!
Timepoint [2]
0
0
Up to 2 years
Query!
Secondary outcome [1]
0
0
Seroconversion of antibodies to AAV8 over time
Query!
Assessment method [1]
0
0
Seroconversion of antibodies to AAV8 will be recorded from serum blood samples collected.
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Secondary outcome [2]
0
0
Creatine kinase [CK] levels
Query!
Assessment method [2]
0
0
CK levels will be recorded from blood plasma samples collected.
Query!
Timepoint [2]
0
0
Up to 2 years
Query!
Secondary outcome [3]
0
0
Urine glucose tetrasaccharide [Glc4]/hexose tetrasaccharide [Hex4] over time
Query!
Assessment method [3]
0
0
Glc4/Hex4 will be recorded from urine samples collected.
Query!
Timepoint [3]
0
0
Up to 2 years
Query!
Secondary outcome [4]
0
0
Occurrence of anti-GAA antibodies in participants on ERT
Query!
Assessment method [4]
0
0
Anti-GAA antibodies will be recorded from serum blood samples collected.
Query!
Timepoint [4]
0
0
Up to 2 years
Query!
Eligibility
Key inclusion criteria
* Participant has a documented clinical diagnosis of LOPD.
* Participant is enzyme replacement therapy (ERT) naïve (ERT-N) or has received any ERT for 6 months or more (ERT-E).
* Participant is willing and able to comply with study visits and procedures.
* Participant agrees to not start participating in any other clinical study involving an investigational study treatment, including ERT, while participating in this study.
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
69
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participant previously received an AAV-related product (any serotype).
* Participant is currently participating in a Pompe-related interventional study (other than ERT-interventional studies) or has received gene or cell therapy.
* Participant requires any invasive or noninvasive ventilation support while awake and upright (non-invasive support while sleeping with either continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) is acceptable for eligibility).
* Participant is unable to ambulate (assistive devices [e.g., cane or walker] are acceptable for eligibility).
* Participants who have received any ERT for less than 6 months as of the Baseline visit are not eligible.
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/05/2027
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
AU61003 - Adelaide
Query!
Recruitment hospital [2]
0
0
AU61001 - Herston
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Herston
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Minnesota
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Virginia
Query!
Country [3]
0
0
France
Query!
State/province [3]
0
0
Angers
Query!
Country [4]
0
0
France
Query!
State/province [4]
0
0
Garches
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Lille
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Limoges
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Marseille
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Nantes
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Nice Cedex 3
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Strasbourg
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hochheim
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Roma
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Kodaira-Shi
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Shinjuku-Ku
Query!
Country [15]
0
0
Spain
Query!
State/province [15]
0
0
Albacete
Query!
Country [16]
0
0
Spain
Query!
State/province [16]
0
0
Barcelona
Query!
Country [17]
0
0
Spain
Query!
State/province [17]
0
0
L'hospitalet de Llobregat
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Madrid
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
San Sebastian
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Valencia
Query!
Country [21]
0
0
Taiwan
Query!
State/province [21]
0
0
Taipei
Query!
Country [22]
0
0
Taiwan
Query!
State/province [22]
0
0
Taoyuan City
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Newcastle upon Tyne
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Astellas Gene Therapies
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards. The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time. Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold. The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells. Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers. In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There will be 2 groups - those who have never had enzyme replacement therapy, and those who have had enzyme replacement therapy for 6 months or more. No study treatment will be given during the study, but blood and urine samples will be taken for testing. The main aims of the study are to check antibody levels against AAV8 (a type of AAV) in people with late-onset Pompe disease who had not received any treatment using AAV, to check antibody levels against the GAA enzyme in people previously treated with GAA as part of enzyme replacement therapy, to check levels of biomarkers for Pompe disease, and to check for medical problems. In the study, people will visit the study clinic several times. Some visits may be in the person's home. The first visit is to check if they can take part. Those who can take part will have a medical examination, and have their vital signs checked. Vital signs include blood pressure, heart rate, breathing rate and temperature. Blood samples will be taken to check antibody levels against the GAA enzyme and against AAV8. Blood and urine samples will also be taken to check for biomarkers for Pompe disease. Blood and urine samples will be taken about every 4 months for up to 2 years.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06150820
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Astellas Gene Therapies
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Astellas Gene Therapies
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
800-888-7704
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06150820